Nivolumab

Nivolumab plus rucaparib demonstrated activity among men with chemotherapy-naive metastatic castration-resistant prostate cancer, according to results of cohort A2 of the CheckMate 9KD trial presented during the virtual ESMO Congress 2021.

The FDA granted priority review to relatlimab and nivolumab for treatment of unresectable or metastatic melanoma.

The combination of nivolumab and ipilimumab maintained its survival advantage over chemotherapy with at least 3 years of follow-up among patients with unresectable malignant pleural mesothelioma, according to CheckMate 743 study results.

First-line nivolumab plus ipilimumab conferred durable survival benefit compared with sunitinib for patients with advanced renal cell carcinoma, according to results of the randomized phase 3 CheckMate-214 trial.

Nivolumab plus ipilimumab conferred a durable survival benefit compared with chemotherapy as first-line treatment for unresectable malignant pleural mesothelioma, according to randomized phase 3 trial data released by the manufacturer.

The addition of nivolumab and ipilimumab to first-line chemotherapy conferred durable survival benefits to patients with advanced non-small cell lung cancer and brain metastases, according to results of the phase 3 CheckMate 9LA trial.

The FDA approved nivolumab for adjuvant treatment of patients with surgically resected, high-risk urothelial carcinoma, according to the agent’s manufacturer.

Bristol Myers Squibb in consultation with the FDA voluntarily withdrew the indication for nivolumab as monotherapy for patients with hepatocellular carcinoma previously treated with sorafenib.

A phase 3 trial of nivolumab plus ipilimumab vs. the EXTREME regimen as first-line treatment of advanced squamous cell carcinoma of the head and neck failed to meet its primary endpoints of OS, according to a company-issued press release.

In this video, Sonam Puri, MD, discusses the surgical outcomes from the phase 3 CheckMate 816 trial presented at this year’s virtual annual ASCO meeting.